Equities research analysts expect that Bausch Health Companies Inc (NYSE:BHC) will announce sales of $1.81 billion for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Bausch Health Companies’ earnings, with the lowest sales estimate coming in at $1.74 billion and the highest estimate coming in at $1.89 billion. Bausch Health Companies posted sales of $2.15 billion in the same quarter last year, which suggests a negative year-over-year growth rate of 15.8%. The firm is scheduled to report its next earnings results on Tuesday, August 4th.
According to Zacks, analysts expect that Bausch Health Companies will report full-year sales of $8.06 billion for the current financial year, with estimates ranging from $7.98 billion to $8.13 billion. For the next fiscal year, analysts expect that the firm will post sales of $8.65 billion, with estimates ranging from $8.42 billion to $8.95 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Bausch Health Companies.
Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.88 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.88. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $2.03 billion. Bausch Health Companies had a negative net margin of 21.96% and a positive return on equity of 84.58%. The business’s revenue was down .2% on a year-over-year basis. During the same period last year, the company earned $1.03 earnings per share.
Several research analysts recently weighed in on BHC shares. ValuEngine upgraded shares of Bausch Health Companies from a “strong sell” rating to a “sell” rating in a report on Thursday, June 25th. SunTrust Banks cut their price target on shares of Bausch Health Companies from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, May 8th. TheStreet cut shares of Bausch Health Companies from a “c-” rating to a “d+” rating in a report on Friday, April 3rd. HC Wainwright boosted their price target on shares of Bausch Health Companies from $50.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Finally, Citigroup started coverage on shares of Bausch Health Companies in a report on Friday, April 24th. They set a “buy” rating and a $30.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Bausch Health Companies has an average rating of “Buy” and a consensus target price of $32.06.
In related news, Director John Paulson purchased 2,041,036 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was acquired at an average price of $17.35 per share, with a total value of $35,411,974.60. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Holdings L.P. Valueact purchased 948,353 shares of the business’s stock in a transaction on Friday, June 5th. The stock was bought at an average cost of $19.24 per share, with a total value of $18,246,311.72. The disclosure for this purchase can be found here. In the last three months, insiders acquired 4,618,309 shares of company stock valued at $79,509,247. Corporate insiders own 12.14% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Envestnet Asset Management Inc. bought a new position in shares of Bausch Health Companies in the 4th quarter worth approximately $1,203,000. Rockefeller Capital Management L.P. bought a new position in shares of Bausch Health Companies in the 1st quarter worth approximately $63,000. Capital World Investors lifted its stake in shares of Bausch Health Companies by 375.5% in the 4th quarter. Capital World Investors now owns 950,922 shares of the company’s stock worth $28,452,000 after purchasing an additional 750,922 shares during the period. The Manufacturers Life Insurance Company raised its stake in Bausch Health Companies by 55.1% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,808,047 shares of the company’s stock worth $27,704,000 after acquiring an additional 642,647 shares during the period. Finally, Credit Suisse AG raised its stake in Bausch Health Companies by 47.0% during the 4th quarter. Credit Suisse AG now owns 785,262 shares of the company’s stock worth $23,495,000 after acquiring an additional 251,201 shares during the period. 68.94% of the stock is owned by institutional investors.
Shares of NYSE BHC traded up $0.10 during mid-day trading on Friday, reaching $18.29. 178,238 shares of the company’s stock traded hands, compared to its average volume of 4,942,722. The stock has a market cap of $6.45 billion, a P/E ratio of -3.39, a PEG ratio of 0.45 and a beta of 1.26. The business has a 50-day simple moving average of $18.28 and a 200 day simple moving average of $22.02. Bausch Health Companies has a 1-year low of $11.15 and a 1-year high of $31.97.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
See Also: What is a management fee?
Get a free copy of the Zacks research report on Bausch Health Companies (BHC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.